Kathleen Hands
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1174558159
Payments from drug & device makers
Across 428 payments — averaging $520.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$119K
- Novo Nordisk$86K
- AbbVie$9K
- Amgen$8K
- IBSA Pharma Inc.$176
- Valeritas, Inc.$139
- plus $384 from 9 others
What the payments were for
- Consulting fees$4,6502%
- Speaking & faculty fees$176,85379%
- Travel & lodging$30,76614%
- Food & beverage$10,2995%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 166 | $118,694 |
| Novo Nordisk | 124 | $85,936 |
| AbbVie | 26 | $9,128 |
| Amgen(2 entities) | 84 | $8,212 |
| IBSA Pharma Inc. | 10 | $176 |
| Valeritas, Inc. | 1 | $139 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Amneal Pharmaceuticals LLC | 4 | $60 |
| Lilly USA, LLC | 4 | $59 |
| Tempus AI, Inc | 2 | $50 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Eisai Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Vistapharm, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$222,670 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SynthroidLevothyroxine Sodium | 107 | $12,312 |
| TirosintLevothyroxine Sodium | 18 | $7,015 |
| DottiEstradiol | 13 | $2,473 |
| ProgesteroneProgesterone, Micronized | 27 | $813 |
| Metformin Hcl ErMetformin Hcl | 17 | $228 |
| Methimazole | 14 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $9,128 | $12,312107 claims |
| IBSA Pharma Inc.Tirosint | $176 | $7,01518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.